BPC 157: Miracle Healing Peptide or Hidden Danger? FDA Proposes Exclusion of Semaglutide, Tirzepatide, Liraglutide from 503B Bulks List FDA posted on the topic LinkedIn The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Sends Warning Letters to More Than 50 GLP 1 Compounders and Manufacturers Wilson Sonsini The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157: Miracle Healing Peptide or Hidden Danger?